US 11,952,397 B2
Crystalline forms of a neuroactive steroid
Shanming Kuang, Plainsboro, NJ (US); and Tianrui Li, Cambridge, NJ (US)
Assigned to Sage Therapeutics, Inc., Cambridge, MA (US)
Filed by Sage Therapeutics, Inc., Cambridge, MA (US)
Filed on Aug. 2, 2023, as Appl. No. 18/363,942.
Application 18/363,942 is a continuation of application No. PCT/US2022/038459, filed on Jul. 27, 2022.
Claims priority of provisional application 63/226,374, filed on Jul. 28, 2021.
Prior Publication US 2023/0374061 A1, Nov. 23, 2023
Int. Cl. C07J 43/00 (2006.01)
CPC C07J 43/003 (2013.01) 7 Claims
 
1. A crystalline form of Compound (1), wherein Compound (1) is represented by the following structural formula:

OG Complex Work Unit Chemistry
wherein the crystalline form is crystalline anhydrous Compound (1), and wherein the crystalline form is characterized by one or more peaks corresponding to 2-theta values measured in degrees of 15.4±0.3, 15.6±0.3, 18.1±0.3, 18.8±0.3, and 22.6±0.3 in an X-ray powder diffraction pattern.